Bioasis Technologies (FRA:107) Short-Term Debt & Capital Lease Obligation : €1.09 Mil (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Bioasis Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2022 was €1.09 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Bioasis Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2022 was €0.52 Mil.

Bioasis Technologies Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Bioasis Technologies's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Short-Term Debt & Capital Lease Obligation Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.34

0.04

1.04

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															1.05	1.04	1.10	1.15	1.09

Bioasis Technologies Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Bioasis Technologies Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies (FRA:107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines